Percutaneous drug delivery systems for improving antifungal therapy effectiveness: A review

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 6, Issue 6, 2014, Pages 8-16

  Glujoy, Maximiliano ^a   Salerno, Claudia ^a   Bregni, Carlos ^a   Carlucci, Adriana M ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Antifungal drug delivery; Cutaneous leishmaniasis; Percutaneous administration; Superficial mycoses

Indexed keywords

ALLYLAMINE; ANTIFUNGAL AGENT; CARBOMER; CLOTRIMAZOLE; CREMOPHOR; DEOXYCHOLATE SODIUM; ECONAZOLE; FLUCONAZOLE; GLYCEROL BEHENATE; GLYCEROL PALMITOSTEARATE; GLYCEROL STEARATE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MIGLYOL; MYRISTIC ACID ISOPROPYL ESTER; NANOPARTICLE; POLOXAMER; POLYACRYLIC ACID; POLYSORBATE 80; POSACONAZOLE; PYRROLE; SINAMIDA; SORBITAN; TERBINAFINE; TRIAZOLE; TYLOXAPOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; FOAM; LIGHT EXPOSURE; MICELLE; MICROEMULSION; MOLECULAR WEIGHT; MYCOSIS; NONHUMAN; PERCUTANEOUS DRUG DELIVERY SYSTEM; PHYSICAL CHEMISTRY; REVIEW;

EID: 84903907297     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. st Ed. Florida USA: BR Jasti, TK Ghosh Editors. CRC Press; 2004: 423-55.
2. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and Transdermal Drug Delivery Systems: Current and Future Prospects. Drug Deliv 2006; 13 Suppl 3: 175-87.
3. Yang Y, Kalluri H, Banga AK. Effects of Chemical and Physical Enhancement Techniques on Transdermal Delivery of Cyanocobalamin (Vitamin B12) In Vitro. Pharmaceutics 2011; Suppl 3: 474-(4)84.
4. Jain S, Jain S., Khare P, Gulbake A, Bansal D, Jain S. K. Design and development of solid lipid nanoparticles for topical delivery of an anti-fungal agent. Drug Deliv 2010; 17 Suppl 6: 443-51.
5. Bachhav YG, Mondon K, Kalia YN, Gurny R, Möller M. Novel micelle formulations to increase cutaneous bioavailability of azole antifungals. J Cont Rel 2011; 153: 126-32.
6. Degreef H, Heeres J, Borgers M. Antifungal azoles for skin disorders. Expert Opin Ther Pat 2006; 16 (9): 1235-53.
7. Shaha V, Jain H, Krishna J, Patel P. Microsponge drug delivery: A review. Int J Res Pharm Sci 2010; 1 (2): 212-8.
8. Yang W, Wiederhold NP, Williams RO. Drug delivery strategies for improved azole antifungal action. Expert Opin Drug Deliv 2008; 11: 1199-216.
9. Millikan LE. Current concepts in systemic and topical therapy for superficial mycoses. Clin Dermatol 2010; 28: 212-6.
10. Chapman SW, Sullivan DC, Cleary JD. In Search of the Holy Grail of Antifungal Therapy. Trans Am Clin Climatol Assoc 2008; 119: 197-216.
11. King CT, Rogers PD, Cleary JD, Chapman SW. Antifungal therapy during pregnancy. Clin Infect Dis 1998; 27 (5): 1151-60.
12. Formulario Terapéutico Nacional 11° Edición, 2011. http://www. comra. org. ar/formulario_terapeutico. pdf. Accessed 01/06/2012.
13. Elewski B, Tavakkol A. Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality. Ther Clin Risk Manag 2005; 1 (4): 299-306.
14. Kaur R, Kashyap B, Bhalla P. Onychomycosis--epidemiology, diagnosis and management. Indian J Med Microbiol 2008; 26 (2): 108-16.
15. Niewerth M, Korting HC. The use of systemic antimycotics in dermatotherapy. Eur J Dermatol. 2000; 10 (2): 155-60.
16. Sundar S, Chatterjee M. Visceral leishmaniasis-current therapeutic modalities. Indian J Med Res 2006; 123: 345-52.
17. Beach DH, Goad LJ, Holz GG. Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Mol Biochem Parasitol 1988; 31 (2): 149-62.
18. Paolicelli, P, Corrente F, Serricchio D, Cerreto F, Cesa S, Tita B, Vitali F. The system SLN-Dextran hydrogel: An application for the topical delivery of ketoconazole. J Chem Pharm Res 2011; 3 (4): 410-21.
19. Gregorí Valdés BS. Estructura y actividad de los antifúngicos. Rev Cubana Farm 2005; 39 (2).
20. Mannisto T, Mantyla R, Nykanen S, Lamminsivu U, Ottoila P. Impairing Effect of Food on Ketoconazole Absorption. Antimicrob Agents Chemother 1982; 730-733.
21. Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 1998; 54: 159-161.
22. Chudasama A, Patel V, Nivsarkar M, Vasu K, Shishoo C. Investigation of microemulsion system for transdermal delivery of itraconazole. J Adv Pharm Tech Res 2011; 2 (1): 30-8.
23. OSPAR 2005 commission update. Administrator of the Oslo and Paris Conventions for the protection of the marine environment of the North-East Atlantic. http://www. ospar. org/documents/dbase/publications/p00199_bd%20on%20clotrimazole. pdf. Accessed 01/06/2012.
24. Beggs WH. Influence of alkaline pH on the direct lethal action of miconazole against Candida albicans. Mycopathologia 1992; 120: 11-13.
25. Florea M, Arama CC, Monciu CM. Determination of terbinafine hydrochloride by ion-pair reversed phase liquid chromatography. Farmacia 2009; 57: 82-8.
26. Kumar N, Jain AK, Singh C, Kumar R. Development, characterization and solubility study of solid dispersion of terbinafine hydrochloride by solvent evaporation method. Asian J Pharm 2008; 2 (3): 154-8.
27. Sampaio RN, Takano GH, Malacarne AC, Pereira TR, de Magalhães AV. In vivo Terbinafine inefficacy on cutaneous leishmaniasis caused by Leishmania amazonensis in C57BL/6 mice. Rev Soc Bras Med Trop 2003; 36 (4): 531-3.
28. Simões-Mattos L, Teixeira MJ, Costa DC, Prata JR, Bevilaqua CM, Sidrim JJ, Rocha MF. Evaluation of terbinafine treatment in Leishmania chagasi-infected hamsters (Mesocricetus auratus). Vet Parasitol 2002; 28: 207-16.
29. Ellepola AN, Panagoda GJ, Samaranayake LP. Adhesion of oral Candida species to human buccal epithelial cells following brief exposure to nystatin. Oral Microbiol Immunol 1999; 14 (6): 358-63.
30. Rajan R, Jose S, Biju Mukund VP, Vasudevan DT. Transferosomes-A vesicular transdermal delivery system for enhanced drug permeation. J Adv Pharm Technol Res. 2011; 2 (3): 138-43.
31. Rakesh R, Anoop KR. Ethosomes for transdermal and topical drug delivery. Review article. Int J Pharm Pharm Sci. 2012; 4 (3): 17-24.
32. Sinico C, Fadda A. M. Vesicular carriers for dermal drug delivery. Expert Opin Drug Deliv 2009; 6 (8): 813-25.
33. Azeem A, Khan ZI, Aqil M, Ahmad FJ, Khar RK, Talegaonkar S. Microemulsions as a surrogate carrier for dermal drug delivery. Drug Dev Ind Pharm 2009; 35: 525-47.
34. Verma P, Pathak K. Nanosized ethanolic vesicles loaded with econazole nitrate for the treatment of deep fungal infections through topical gel formulation. Nanomedicine 2012; 8 (4): 489-96.
35. Nounou MM, El-Khordagui LK, Khalafallah NA, Khalil SA. Liposomal formulation for dermal and transdermal drug delivery: Past, present and future. Recent Pat Drug Deliv Formul 2008; 2 (1): 9-18.
36. Gupta M, Goyal AK, Paliwal SR, Paliwal R, Mishra N, Vaidya B et al. Development and characterization of effective topical liposomal system for localized treatment of cutaneous candidiasis. J Lipos Res 2010; 20 (4): 341-50.
37. Shaikh KS, Pawar AP. Liposomal delivery enhances cutaneous availability of ciclopirox olamine. Lat Am J Pharm 2010; 29 (5): 763-70.
38. Rajnish A, Ajay S. Release studies of ketoconazole niosome formulation. Journal of Global Pharma Technology 2010; 2 (1): 125-7.
39. Sathali AAH, Rajalakshmi G. Evaluation of Transdermal Targeted Niosomal Drug Delivery of Terbinafine Hydrochloride. Int J Pharm Tech Res 2010; 2 (3): 2081-9.
40. Ning M, Gu Z, Pan H, Yu H, Xiao K. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antifungal drug clotrimazole. Indian J Exp Biol 2005; 43 (2): 150-7.
41. Ning M, Guo Y, Pan H, Chen X, Gu Z. Preparation, in Vitro and in Vivo Evaluation of Liposomal/Niosomal Gel Delivery Systems for Clotrimazole. Drug Dev Ind Pharm 2005; 31: 375-83.
42. Karimunnisa S, Atmaram P. Mucoadhesive nanoliposomal formulation for vaginal delivery of an antifungal. Drug Dev Ind Pharm 2012 Aug 7.
43. Elmoslemany RM, Abdallah OY, El-Khordagui LK, Khalafallah NM. Propylene glycol liposomes as a topical delivery system for miconazole nitrate: comparison with conventional liposomes. AAPS PharmSciTech 2012; 13(2): 723-31.
44. Bhalaria MK, Naik S, Misra A. N. Ethosomes: A novel delivery system for antifungal drugs in the treatment of topical fungal diseases. Indian J Exp Biol 2009; 47 (5): 368-75.
45. Akhtar N, Pathak K. Cavamax W7 composite ethosomal gel of clotrimazole for improved topical delivery: development and comparison with ethosomal gel. AAPS PharmSciTech 2012; 13(1): 344-55.
46. Ghannoum M, Isham N, Herbert J, Henry W, Yurdakul S. Activity of TDT 067 (Terbinafine in Transfersome®) against Agents of Onychomycosis, as Determined by Minimum Inhibitory and Fungicidal Concentrations. J Clin Microbiol 2011; 49 (5): 1716-20.
47. Zhang JP, Wei YH, Zhou Y, Li YQ, Wu XA. Ethosomes, binary ethosomes and transfersomes of terbinafine hydrochloride: a comparative study. Arch Pharm Res 2012; 35(1): 109-17.
48. Reshmy Rajan and Deepa T. Vasudevan. Effect of permeation enhancers on the penetration mechanism of transferosomal gel of ketoconazole. J Adv Pharm Technol Res 2012 Apr-Jun; 3(2): 112-16.
49. Aggarwal N, Goindi S. Preparation and evaluation of antifungal efficacy of griseofulvin loaded deformable membrane vesicles in optimized guinea pig model of Microsporum canis-Dermatophytosis. Int J Pharm 2012 Nov 1; 437 (1-2): 277-87.
50. Kaur IP, Rana C, Singh M, Bhushan S, Singh H, Kakkar S. Development and evaluation of novel surfactant-based elastic vesicular system for ocular delivery of fluconazole. J Ocul Pharmacol Ther 2012; 28(5): 484-96.
51. Song CK, Balakrishnan P, Shim CK, Chung SJ, Chong S, Kim DD. A novel vesicular carrier, transethosome, for enhanced skin delivery of voriconazole: characterization and in vitro/in vivo evaluation. Colloids Surf B Biointerfaces 2012; 92: 299-304.
52. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-77.
53. Souto EB, Wissing SA, Barbosa CM, Müller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004; 278(1): 71-7.
54. Souto EB, Müller RH. SLN and NLC for topical delivery of ketoconazole. J Microencapsul 2005; 22(5): 501-10.
55. Souto EB, Müller RH. Investigation of the factors influencing the incorporation of clotrimazole in SLN and NLC prepared by hot high-pressure homogenization. J Microencapsul 2006; 23(4): 377-88.
56. Souto EB, Müller RH. The use of SLN and NLC as topical particulate carriers for imidazole antifungal agents. Pharmazie 2006; 61(5): 431-7.
57. Jain S, Jain S, Khare P, Gulbake A, Bansal D, Jain S. K. Design and development of solid lipid nanoparticles for topical delivery of an anti-fungal agent. Drug Deliv 2010; 17 (6): 443-51.
58. Bhalekar MR, Pokharkar V, Madgulkar A, Patil N, Patil N. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech 2009; 10 (1): 289-96.
59. Sanna V, Mariani A, Caria G, Sechi M. Synthesis and evaluation of different fatty acid esters formulated into Precirol® ATO-based lipid nanoparticles as vehicles for topical delivery. Chem Pharmaceut Bull 2009; 57 (7): 680-4.
60. Ying-Chen Chen, Der-Zen Liu, Jun-Jen Liu, Tsung-Wei Chang, Hsiu-O Ho, Ming-Thau Sheu. Development of terbinafine solid lipid nanoparticles as a topical delivery system. Int J Nanomedicine 2012: 7 4409-4418.
61. Prasad V, Kumar N, Mishra PR. Amphiphilic Gels as a Potential Carrier for Topical Drug Delivery. Drug Deliv 2007; 14: 75-85.
62. Lalit SK, Panwar AS, Darwhekar G, Jain D. K. Formulation and evaluation of fluconazole amphiphilogel. Der Pharmacia Lettre 2011; 3 (5): 125-31.
63. Deveda P, Jain A, Vyas N, Khambete H, Jain S. Gellified emulsion for sustain delivery of itraconazole for topical fungal diseases. Int J Pharm Sci 2010; 2 (1): 104-12.
64. Shahin M, Hady SA, Hammad M, Mortada N. Optimized formulation for topical administration of clotrimazole using Pemulen polymeric emulsifier. Drug Dev Ind Pharm 2011; 37 (5): 559-68.
65. Patel SB, Patel HJ, Seth AK. Microsponge drug delivery system: An overview. Journal of Global Pharma Technology 2010; 2 (8): 1-9.
66. Saboji JK, Manvi F V, Gadad A P, Patel Formulation and evaluation of ketoconazole microsponge by quassi emulsion BD. solvent diffusion. J Cell and Tissue Research 2011; 11 (1): 2691-6.
67. Zhao Y, Jones SA, Brown MB. Dynamic foams in topical drug delivery. J Pharm Pharmacol 2010; 62 (6): 678-84.
68. Tamarkin D, Friedman D, Shemer A. Emollient foam in topical drug delivery. Expert Opin Drug Deliv 2006; 3 (6): 799-807.
69. Mehta K, Bhatt DC. Preparation, optimization and in vitro microbiological efficacy of antifungal microemulsion. Int J Pharm Sci Res 2011; 2 (9): 2424-9.
70. Peira E, Carlotti ME, Trotta C, Cavalli R, Trotta M. Positively charged microemulsions for topical application. Int J Pharm 2008; 346 (1-2): 119-23.
71. El Laithy HM, El-Shaboury KM. The development of Cutina lipogels and gel microemulsion for topical administration of fluconazole. AAPS PharmSciTech 2002; 3 (4): E35.
72. Jadhav KR, Shetye SL, Kadam VJ. Design and evaluation of microemulsion based drug delivery system. Int J Adv Pharm Sci 2010; 1 (2): 156-66.
73. Jadhav KR, Kadam VJ, Pisal SS. Formulation and evaluation of lecithin organogel for topical delivery of fluconazole. Current Drug Deliv 2009; 6 (2): 174-83.
74. Patel MR, Patel RB, Parikh JR, Solanki AB, Patel BG. Effect of Formulation Components on the In Vitro Permeation of Microemulsion Drug Delivery System of Fluconazole. AAPS PharmSciTech 2009; 10, (3): 917-23.
75. Shah RR, Magdum CS, Wadkar KA, Naikwade NS. Fluconazole Topical Microemulsion: Preparation and Evaluation. Res J Pharm Tech 2009; 2 (2): 353-7.
76. Salerno C, Carlucci A, Bregni C. Study of in vitro drug release and percutaneous absorption of fluconazole from topical dosage forms. AAPS PharmaSciTech 2010; 11 (2); 986-93.
77. Patel MR, Patel RB, Parikh JR, Solanki AB, Patel BG. Investigating effect of microemulsion components: In vitro permeation of ketoconazole. Pharm Dev Technol 2011 Jun; 16(3): 250-8.
78. Hashem FM, Shaker DS, Ghorab MK, Nasr M, Ismail A. Formulation, characterization, and clinical evaluation of microemulsion containing clotrimazole for topical delivery. AAPS PharmSciTech 2011; 12 (3): 879-86.
79. Baboota S, Al-Azaki A, Kohli K, Ali J, Dixit N, Shakeel F. Development and evaluation of a microemulsion formulation for transdermal delivery of terbinafine. J Pharm Sci Technol 2007; 61 (4): 276-85.
80. Barot BS, Parejiya PB, Patel HK, Gohel MC, Shelat PK. Microemulsion-based gel of terbinafine for the treatment of onychomycosis: optimization of formulation using D-optimal design. AAPS PharmSciTech 2012; 13(1): 184-92.
81. El-Hadidy GN, Ibrahim HK, Mohamed MI, El-Milligi MF. Microemulsions as vehicles for topical administration of voriconazole: formulation and in vitro evaluation. Drug Dev Ind Pharm 2012; 38(1): 64-72.
82. Nuzhat Tabassum & Vidayasagar GM. Antifungal investigations on plant essential oils. A review. Int J Pharm Pharm Sci. 2013 (5) suppl 2: 19-28.
83. Savic S, Lukic M, Jaksic I, Reichl S, Tamburic S, Müller-Goymann C. An alkyl polyglucoside-mixed emulsifier as stabilizer of emulsion systems: the influence of colloidal structure on emulsions skin hydration potential. J Colloid Interface Sci 2011; 358 (1): 182-91.
84. Kirjavainen M, Mönkkönen J, Saukkosaari M, Valjakka-Koskela R, Kiesvaara J, Urtti A. Phospholipids affect stratum corneum lipid bilayer fluidity and drug partitioning into the bilayers. J Control Release 1999; 58 (2): 207-14.
85. Kreilgaard M, Pedersen EJ, Jaroszewski JW. NMR characterisation and transdermal drug delivery potential of microemulsion systems. J Control Release 2000; 69 (3): 421-33.
86. Tenjarla S. Microemulsions: an overview and pharmaceutical applications. Crit Rev Ther Drug Carrier Syst 1999; 16 (5): 461-521.
87. Ghosh PK, Murthy RS. Microemulsions: a potential drug delivery system. Curr Drug Deliv 2006; 2: 167-80.
88. Turi JS, Danielson D, Woltersom JW. Effects of polyoxypropylene 15 stearyl ether and propylene glycol on percutaneous penetration rate of diflorasone diacetate. J Pharm Sci 1979; 68 (3): 275-80.
89. Özcan I, Abaci Ö, Uztan AH, Aksu B, Boyacioǧlu H, Güneri T, Özer Ö. Enhanced topical delivery of terbinafine hydrochloride with chitosan hydrogels. AAPS PharmSciTech 2009; 10 (3): 1024-31.
90. Carpentieri-Rodrigues LN, Zanluchi J M, Grebogi IH. Percutaneous absorption enhancers: mechanisms and potential. Braz Arch Biol Technol 2007; 50 (6): 949. 61.
91. Evenbratt H, Faergemann J. Effect of pentane-1, 5-diol and propane-1, 2-diol on percutaneous absorption of terbinafine. Acta Derm-Venereol 2009; 89 (2): 126-9.
92. Nair AB, Chakraborty B, Murthy SN. Effect of polyethylene glycols on the trans-ungual delivery of terbinafine. Curr Drug Deliv 2010; 7 (5): 407-14.
93. Shishu;, Aggarwal, N. Preparation of hydrogels of griseofulvin for dermal application. Int J Pharm 2006; 326 (1-2): 20-4.
94. Salerno C, Carlucci AM, Chiappetta D, Bregni C. Inhibition of fluconazole in vitro in antifungal activity in formulation containing propylene glycol. Lat Am J Pharm 2011; 30 (7) 1406-13.
95. Aggarwal N, Goindi S, Mehta SD. Preparation and evaluation of dermal delivery system of griseofulvin containing vitamin E-TPGS as penetration enhancer. AAPS PharmSciTech 2012; 13(1): 67-74.
96. Traynor MJ, Turner RB, Evans CR, Khengar RH, Jones SA, Brown MB. Effect of a novel penetration enhancer on the ungual permeation of two antifungal agents. J Pharm Pharmacol 2010; 62(6): 730-7002E.